We aim to estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH at 12 months after end of gonadotoxic treatment (EoT) in women with breast cancer, but the study will also include subjects receiving less gonadotoxic treatment, such as the primary treatment of acute leukaemia, as well as subjects receiving very high gonadotoxic treatment, such as treatment of sarcoma, both diseases with a high incidence among teenagers. Here, AMH is linked to breast carcinoma.